Top

Clinical Reviews in Allergy & Immunology

Published in:

01-04-2007

APS—More Systemic Disease than SLE

Author: Yehuda Shoenfeld

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2007

Abstract

The antiphospholipid syndrome is a systemic autoimmune disease that can have serious consequences for patients. Importantly, there is a wide range of clinical presentations. In this issue we have attempted to provide an overview of these features and place it in the context of autoimmunity.

Shoenfeld Y (2003) Systemic antiphospholipid syndrome. Lupus 12:497–498PubMedCrossRef

Marai I, Zandman-Goddard G, Shoenfeld Y (2004) The systemic nature of the antiphospholipid syndrome. Scand J Rheumatol 33:365–372PubMedCrossRef

Vasoo S, Sangle S, Zain M, DwCruz D, Hughes G (2005) Orthopaedic manifestations of the antiphospholipid (Huges) syndrome. Lupus 15:339–345CrossRef

Ben-Ami D, Bar-Meir E, Shoenfeld Y (2006) Stenosis in antiphospholipid syndrome: a new finding with clinical implications. Lupus 15:1–5CrossRef

Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34:501–537PubMedCrossRef

Abbas AK, Lohr J, Knoechel B (2007) Balancing autoaggressive and protective T cell responses. J Autoimmmun 28:59–61CrossRef

Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, Cubillas-Tejeda AC, Gonzalez-Amaro R (2006) Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27:110–118PubMedCrossRef

Cavazzana I, Manuela N, Irene C, Barbara A, Sara S, Orietta BM, Angela T, Francesco T, Luigi MP (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28:160–164PubMedCrossRef

Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, Voll RE, Winkler T, Kuhn A, Kalden J, Kern P, Herrmann M (2007) Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 28:114–121CrossRef

10.

Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB (2007) Epidemiology of autoimmune diseases in Denmark. J Autoimmun 29:1–9PubMedCrossRef

11.

Gleicher N, Barad DH (2007) Gender as risk factor for autoimmune diseases. J Autoimmun 28:1–6PubMedCrossRef

12.

Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL (2006) Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 27:266–271PubMedCrossRef

13.

Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmun 28:129–133PubMedCrossRef

14.

Languren M, Becerril B, Cabral AR, Fernandez-Altuna LE, Pascual V, Hernandez-Ramirez DF, Cabiedes J (2006) Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome. J Autoimmun 26:57–65PubMedCrossRef

15.

Ross CJ, Katzov H, Carleton B, Hayden MR (2007) Pharmacogenomics and its implications for autoimmune disease. J Autoimmun 28:122–128PubMedCrossRef

16.

Ambrozic A, Cucnik S, Tomsic N, Urbanija J, Lokar M, Babnik B, Rozman B, Iglic A, Kralj-Iglic V (2006) Interaction of giant phospholipid vesicles containing cardiolipin and cholesterol with beta2-glycoprotein-I and anti-beta2-glycoprotein-I antibodies. Autoimmunity Reviews 6:10–15PubMedCrossRef

17.

Asherson RA (2006) New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmunity Reviews 6:76–80PubMedCrossRef

18.

Bagnasco M, Grassia L, Pesce G (2007) The management of the patient with unexpected autoantibody positivity. Autoimmunity Reviews 6:347–353PubMedCrossRef

19.

Bianco GA, Toscano MA, Ilarregui JM, Rabinovich GA (2006) Impact of protein-glycan interactions in the regulation of autoimmunity and chronic inflammation. Autoimmunity Reviews 5:349–356PubMedCrossRef

20.

Bucciarelli S, Cervera R, Espinosa G, GomezPuerta JA, Ramos-Casals M, Font J (2006) Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmunity Reviews 6:72–75PubMedCrossRef

Title: APS—More Systemic Disease than SLE
Author: Yehuda Shoenfeld
Publication date: 01-04-2007
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2007
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-007-0005-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

APS—More Systemic Disease than SLE

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Systemic Antiphospholipid Syndrome and Atherosclerosis

Antiphospholipid Syndrome and Cancer

Orthopedic Involvement in Antiphospholipid Syndrome

Novel Insights Into Associations of Antibodies Against Cardiolipin and beta2-glycoprotein I with Clinical Features of Antiphospholipid Syndrome

Pulmonary Hypertension, Antiphospholipid Antibodies, and Syndromes

Primary Anetoderma and Antiphospholipid Antibodies—Review of the Literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page